ArticleFrontiers in oncology2025
The post-orchiectomy systemic inflammatory index is associated with tumor characteristics in clinical stage I germ cell tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complete Blood Count-Derived Inflammatory Markers and C-Reactive Protein in Testicular Cancer: Diagnostic and Prognostic Utility.Medical sciences (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 25% to 30% of clinical stage I (CSI) germ cell cancer (GCT) patients will experience disease relapse after an orchiectomy. Adding adjuvant treatment will decrease the relapse rate but could lead to over-treatment. Prognostic biomarkers such as lymphovascular invasion (LVI) and/or embryonal carcinoma (EC) in non-seminoma (NSGCT) and rete testis invasion (RTI) and/or primary tumor size (PTS) in seminoma (SGCT) add limited value in treatment decision- making. The aim of this study is to assess the systemic inflammatory index (SII) and lactate-dehydrogenase (LDH) with clinicopathological findings along with their prognostic impact. Methods: This is a retrospective study that included 159 diagnosed CSI GCT patients, who underwent active surveillance (AS) from June 2004 to November 2023. Medical records and pathology reports were collected retrospectively. Drawn blood must have been done less than 3 months after the orchiectomy had been done. For the survival analysis, we used dichotomized values of the studied biomarkers from "low" to "high" based on the median values. Results: The median follow-up time was 61 months (ranging from 1 to 230 months), with 2-year relapse- free survival (RFS) of 81.3% and 69.0% in SGCT and NSGCT, respectively. We confirm inferior RFS in the presence of LVI compared to an absence of LVI in NSGCT ([HR]= 2.59, 95%CI (0.74-9.07), p=0.04). A trend of inferior RFS in NSGCT patients with EC predominance (≥50%) was also observed ([HR]= 2.59, 95%CI (0.98-6.85), p=0.06). A prognostic impact of RTI and a PTS >4cm in SGCT was not observed with p=0.24 and p=0.51, respectively. The SII was assessed in the population, and a higher neutrophil- to- lymphocyte ratio (NLR) value was associated with LVI presence and with advanced tumor stage in NSGCT. In SGCT, a higher SII level was associated with LVI presence and advanced pathological stage. A PTS >4cm was associated with a higher LDH level among all the studied patients, without significance in SGCT or NSGCT. A higher LDH value in NSGCT was also associated with EC predominance (≥50%). Conclusion: Our study, for the first time, revealed associations of post-orchiectomy systemic inflammatory indices and/or LDH in CSI GCT. These new associations deserve further evaluation in a larger cohort of patients with CSI GCT to elucidate whether its associations in certain histology subgroups will improve the stratification of the at-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.